Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive topical therapies for ophthalmic diseases.
United States of America OCS
ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea 226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America ONCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.